1/5/2010

The FDA granted priority-review status for InterMune's drug candidate for idiopathic pulmonary fibrosis. Pirfenidone, which demonstrated anti-fibrotic and anti-inflammatory effects in preclinical studies, is expected to receive final judgment from the FDA on May 4.

Related Summaries